Soliton to announce fibrotic scar study results at Maui Derm meeting

January 17, 2020

Medical device company, Soliton will present results from their 12-week study looking at the treatment of fibrotic scars using their RAP device at Maui Derm Jan. 25-29.

Soliton, a novel medical device company based out of Houston, Tx, have announced they will debut their 12-week study results examining its Rapid Acoustic Pulse (RAP) device for the treatment of keloids and hypertrophic scars at the Maui Derm meeting Jan. 25-29.

Soliton’s RAP device utilizes rapid pulses of acoustic shockwaves for the removal of tattoos and is also investigating other uses for the device including fat reduction, cellulite improvement and fibrotic scars treatment.

"There was an average reduction in the volume of the scars treated of 27% at the 6-week timepoint. We look forward to being able to share the 12-week results with our shareholders and all interested parties as quickly as possible after the conference,” says Christopher Capelli, M.D., founder, president and CEO of Soliton.

There are scarce treatment options for keloids and hypertrophic scars, with one of the most common being steroid injections into the scar. However, according to the press release, this treatment option could possibly necessitate numerous additional injections and results may not be permanent.

While not currently available on the market, the RAP device is Soliton’s first cleared product by the U.S. Food and Drug Administration (FDA).

READ MORE: Newer multi-modal approaches to treat keloids

References:

Soliton, Inc. Soliton To Announce Keloid and Hypertrophic Scar Clinical 12-Week Trial Data at Maui Derm Meeting. PR Newswire: press release distribution, targeting, monitoring and marketing. https://www.prnewswire.com/news-releases/soliton-to-announce-keloid-and-hypertrophic-scar-clinical-12-week-trial-data-at-maui-derm-meeting-300985456.html. Published January 13, 2020. Accessed January 17, 2020.